LitAlert ~~ GeneLit.com

    • We All Love a Good Book or Movie.
    • [No author given]
    • FORCE. Blog. 2023 Jan 23.
    • Whole-exome sequencing and bioinformatic analyses revealed differences in gene mutation profiles in papillary thyroid cancer patients with and without benign thyroid goitre background.
    • Eng ZH, Abdullah MI, Ng KL, Abdul Aziz A, Arba'ie NH, Mat Rashid N, Mat Junit S.
    • Front Endocrinol (Lausanne). 2023 Jan 4;13:1039494. doi: 10.3389/fendo.2022.1039494.
    • Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3).
    • Aleissa MS, Al-Zharani M, Alneghery LM, Aleissa AM.
    • Saudi Pharm J. 2023 Jan;31(1):110-118. doi: 10.1016/j.jsps.2022.11.009. Epub 2022 Nov 15.
    • Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
    • Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, Jia L, Chen HD, Bao XB, Guo N, Huan XJ, Xi Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Chen Y, Ding J, Lang JY, Miao ZH, Zhang A, He JX.
    • EMBO Mol Med. 2023 Jan 18:e16235. doi: 10.15252/emmm.202216235. Epub ahead of print.
    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.
    • Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis.
    • Bak SE, Kim H, Ho JY, Cho EH, Lee J, Youn SM, Park SW, Han MR, Hur SY, Lee SJ, Choi YJ.
    • Cancers (Basel). 2023 Jan 15;15(2):530. doi: 10.3390/cancers15020530.
  • LitAlert ~~ GeneLit.com

    • Lestaurtinib induces DNA damage that is related to estrogen receptor activation.
    • Ooka M, Yang S, Zhang L, Kojima K, Huang R, Hirota K, Takeda S, Xia M.
    • Curr Res Toxicol. 2022 Dec 24;4:100102. doi: 10.1016/j.crtox.2022.100102.
    • Ferroptosis synergistically sensitizes wee1 inhibitors: a bibliometric study.
    • Xu R, Wu X, Zhao Q, Yang Q.
    • Am J Transl Res. 2022 Dec 15;14(12):8473-8488.
  • LitAlert ~~ GeneLit.com

    • Environmental impact on carcinogenesis under BRCA1 haploinsufficiency.
    • Toyokuni S, Kong Y, Motooka Y, Akatsuka S.
    • Genes Environ. 2023 Jan 13;45(1):2. doi: 10.1186/s41021-023-00258-5.
    • Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes.
    • Ibnat N, Chowdhury EH.
    • Sci Rep. 2023 Jan 11;13(1):536. doi: 10.1038/s41598-022-25511-9.
    • Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes.
    • Ibnat N, Chowdhury EH.
    • Sci Rep. 2023 Jan 11;13(1):536. doi: 10.1038/s41598-022-25511-9.
  • LitAlert ~~ GeneLit.com

    • Update: Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations.
    • [No author given]
    • FORCE. XRAY. 2023 Jan 9.

    •• Identifier: NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers.
    • [No author given]
    • Precision Oncology News. 2023 Jan 9.
    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.
    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
    • Ideaya Biosciences Files IND With FDA for PARG Inhibitor.
    • [No author goven]
    • Precision Oncology News. 2022 Dec 12.
    • Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
    • Chang T, Lian Z, Ma S, Liang Z, Ma X, Wen X, Wang Y, Liu R.
    • Prostate. 2022 Dec 28. doi: 10.1002/pros.24479. Epub ahead of print.